NEOGENOMICS,INC # OTC : NOGN # Wer hat Infos ??? - 500 Beiträge pro Seite

[DNAPSPAZ]

Hallo,ich bin beim rumstöbern auf div.DNAP-Boards auf folgende company gestossen - wer hat Infos über die Firma? (evtl.WKN)

NOGN -- NeoGenomics Inc. (NV)
Com (No Par)

Address:
7103 Pine Bluffs Trail
Austin
TX 78729
USA
Phone: [phone]


Officers:
Dain Schult, Pres.

Shares Outstanding: 18,487,888 as of 2000-09-15

Estimated Market Cap: 351,270 as of 2002-01-18

Current Capital Change:
shs increased by 4 for 1 split
Ex-Date: 2000-11-17
Record Date: 2000-11-06
Pay Date: 2000-11-16


2.1 Agreement and Plan of Exchange dated November 14, 2001, by and among
American Communications Enterprises, Inc., Tampa Bay Financial, Inc.,
Neogenomics, Inc. and Michael T. Dent, M.D. (previously filed as Exhibit 2.1 to
the Registrant`s Quarterly Report on Form 10-Q for the period ended September
30, 2001).

Scnönes WE - Croko

[morchel]

131,733,896 Common Shares

lt letztem 10QSB Filing!

morchel

[DNAPSPAZ]

up

@alle...

War das alles ?

Croko

[DNAPSPAZ]

Such mir meine infos eben selbst

NAPLES, Fla., Jan. 14 /PRNewswire/ -- American Communications Enterprises, Inc. (OTC Bulletin Board: ACEN) announces the change of its name and stock symbol. The Company has recently changed its name to NeoGenomics, Inc. Effective today, the Company`s common stock will be traded on the Nasdaq OTC Bulletin Board under the new symbol NOGN (OTC Bulletin Board: NOGN). The name change reflects the new direction of the Company to that of a genome-based medical research company.

NeoGenomics, Inc.`s principal goal will be to conduct genetic research and develop products for the early diagnosis of women`s diseases, such as ovarian cancer, and diseases in prenatal infants. At the same time, the Company will perform genetic diagnostic procedures for outside clients by establishing a state-of-the-art genetic/diagnostic or "Genostics" laboratory. This is expected to provide NeoGenomics with an ongoing source of working capital, which it will use to support the research division of the Company`s business. For more information about NeoGenomics, visit www.Neogenomics.org.

For additional information and/or a NeoGenomics information package, please contact Ms. Natalia Sherman at [phone], or by email at nsherman@@tbfcorp.net.

Croko

[DNAPSPAZ]

Friday November 16, 10:42 am Eastern Time
Press Release
SOURCE: American Communications Enterprises, Inc.
American Communications Enterprises, Inc. Finalizes The Acquisition of NeoGenomics, Inc.
SARASOTA, Fla., Nov. 16 /PRNewswire/ -- American Communications Enterprises, Inc. (OTC Bulletin Board: ACEN - news) announced today that it has finalized the acquisition of NeoGenomics, Inc. of Naples, Florida.

ACEN believes that NeoGenomics, Inc. will be the first genetic/diagnostic or ``Genostics`` laboratory, devoting its research to the early diagnosis of women`s diseases, such as ovarian cancer, and diseases in prenatal infants. At the same time the Company will utilize its state of the art laboratory facilities to perform existing diagnostic procedures for outside clients. This will provide NeoGenomics with an immediate method of providing additional capital for the research division of the company`s business.

Dr. Michael Dent, a board certified Ob/Gyn and Chairman / President of NeoGenomics, is also the founder and CEO of Naples Women`s Center, which is one of the largest and most prestigious practices of its kind in the Southwest Florida area.

One of the biggest challenges to Genomic researchers is the collection of patients` blood and tissue samples linked to their corresponding phenotypic data. Dr. Dent has an existing patient base of approximately 8,000 from which he can immediately develop his specimen database, giving NeoGenomics a substantial head start. This databank will not only be beneficial to NeoGenomics but could have significant value to the genomics community and may provide the Company with an additional source for future revenue and strategic partnerships.

Dr. Dent states, ``NeoGenomics` facilities provide state-of-the-art equipment, for research in the fields of oncogenomics and proteinomics. The acquisition of NeoGenomics by American Communications Enterprises, Inc. will assist NeoGenomics` efforts in becoming a major facility for R&D/Diagnostic Testing in the biotech sector.``

American Communications Enterprises, Inc. officials stated that, ``NeoGenomics, Inc. provides our Company and its shareholders with the opportunity to become an integral part of the exploding genomics/biotech industry.``

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, competitive pressures, the company`s ability to successfully implement traffic, constantly changing technology, associated with recently formed entities. As a result, this press release should be read in conjunction with the Company`s periodic filings with the SEC.

For additional information and/or a NeoGenomics Information Package please contact Ms. Natalia Sherman at [phone] or by e-mail at [e-mail].

SOURCE: American Communications Enterprises, Inc.